AML MRD ASSAY

Are you ready for molecular MRD detection with greater sensitivity?

TwinStrand’s AML MRD assay is the only error-corrected Next-Generation Sequencing (NGS)-based technology that provides ultrasensitive detection with variant identification down to <0.01% limit of detection.

Variant identification down to 1 in 10,000 limit of detection

Sensitive detection of MRD-associated mutations in AML enables accurate response quantification and remission identification. Our AML MRD assay provides significantly greater sensitivity and accuracy for detecting ultra-low frequency mutations than traditionally used methods such as Multiparameter Flow Cytometry (MFC) and standard NGS panels.

Unmatched specificity and analytical sensitivity

Duplex Sequencing technology eliminates background errors for a > 10,000-fold increase in sensitivity over standard NGS

AML MRD assay outperformed MFC to more accurately identify adult reLAPse subjects

Initial samples taken post-treatment for AML were tested for MRD using our AML MRD assay or and MFC.
In this retrospective research study, variant detection in DNA from remission samples by Duplex Sequencing and subsequent assignment of molecular MRD status showed a stronger than MFC association with relapse-free survival, time to relapse, and overall survival.

Detection of AML-associated mutations at <0.01% VAF

Our AML MRD assay covers key mutations in current testing guidelines

ASXL1	BCOR	BRAF	CALR	CBL	CEBPA
CSF3R	DDX41	DNMT3A	ETV6	EZH2	FLT3
GATA2	IDH1	IDH2	JAK2	KIT	KRAS
MPL	NPM1	NRAS	PHF6	PPM1D	PTEN
PTPN11	RAD21	RUNX1	SETBP1	SF3B1	SRSF2
STAG2	TET2	TP53	U2AF1	WT1	ZRSR2